Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar sodium + venetoclax + azacitidine for relapsed/refractory acute myeloid leukemia
ChiCTR2500097595Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chiglitazar, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete remission. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
chiglitazarvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500097595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097595.